ArticleScientific reports2025
Analyzing the effects of benzodiazepines on the virulence and biofilm formation of Pseudomonas aeruginosa.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural and synthetic chemicals acting as enhancers of bacterial pathogenic success within the human host.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Sedation with benzodiazepines (BZs) has eventual side-effects increasing the risk for ventilator-associated pneumonia (VAP) (e.g. immunity alterations and nervous/mechanical responses), but there are some knowledge gaps on the topic. For instance, whether BZs could cause a modulation of bacterial virulence, and/or influence the host-pathogen interaction in neglected contexts to facilitate VAP. Consequently, we analyzed relevant in vitro and in vivo infection-related parameters to decipher whether they could be affected by BZs to increase the success for infection of the top VAP-causing pathogen Pseudomonas aeruginosa. While most variables were unaltered, an attenuated pathogenic impact on lung A549 cells (invasion, cytotoxicity and inflammation reduced up to ≈ 50%) appeared upon BZs exposure at high therapeutic concentrations, potentially because of effects mostly on the cultured cells. These facts could entail a BZs-associated stealth pathogen-like behavior of P. aeruginosa consisting of a weak immune activation proportional to the mild damage caused, perhaps favoring VAP onset. BZs also triggered a significantly increased biofilm formation (up to ≈ 2-fold > controls) on plastic plates and endotracheal tubes (supported by the upregulation of biofilm-related genes/KEGG pathways and increased c-di-GMP accumulation), suggesting the BZ-dependent boosted formation of these sessile reservoirs which could potentially increase bacterial release to low airways and thus VAP progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.